Come see us at #NASCI2026 today for a hands-on look at Elucid’s CT analysis software offering plaque analysis and BioIntegrated FFR-CT*! #CCTA #cardiovascularimaging #atherosclerosis #cardiology *FFR-CT is under FDA review.

#VPM2026 was simply stellar, as always. We’re still reflecting on the ideas, science, and conversations that came out of this year’s meeting. Bringing together experts from across the field to openly exchange perspectives on vulnerable plaque, atherosclerosis, and the future of cardiovascular care is what makes VPM such a valuable forum. Thank you to everyone who shared their expertise, challenged conventional thinking, and left us with new ideas and inspiration to bring back to our work at Elucid 🫀🧠 Stay tuned for our presentations from the meeting! #vulnerableplaque #cardiovascularimaging #atherosclerosis #CCTA

Elucid is proud to support and exhibit at @NASCISociety Annual Meeting, September 26–29 in Denver. Stop by our booth for a hands-on look at our latest developments and see how we’re advancing CCTA beyond anatomy alone, bringing together anatomy, plaque biology, and physiology for a more complete view of coronary disease. We’re looking forward to connecting with the cardiovascular imaging community, sharing ideas, and demonstrating what becomes possible with Elucid. See you at NASCI! Lesion-Level Risk → Patient-Level Impact #NASCI2026 #CCTA #cardiacCT #cardiovascularimaging #cardiology

❗JUST ANNOUNCED❗ A major milestone for Elucid—and for the future we’re building in cardiovascular care. Read here: elucid.com/elucid-raises-55-… We’re proud to announce the closing of an oversubscribed $55 million Series D financing, bringing Elucid’s total funding raised to approximately $185 million. The round includes new participation from a leading medtech company—our fourth publicly traded strategic investor—alongside new and existing investors. Ultimately, this milestone is about what comes next. As CEO Kelly Huang, PhD, shared: “Analogous to oncology’s shift from population-based, one-size treatment, Elucid is applying AI to integrate anatomy, biology, and physiology to bring personalized treatment to coronary artery disease management.” We’re grateful to our investors, partners, customers, and the entire Elucid team for helping us reach this moment. There’s much more ahead!! #cardiology #cardiovascularimaging #yesCCT #artificialintelligence #medtech #precisionmedicine

We’re honored to support the Imperial Vulnerable Plaque and Patient Meeting (VPM) for another year! VPM brings together some of the leading minds in atherosclerosis, cardiovascular imaging, and intervention for the kind of focused scientific exchange that makes this meeting so special. This year’s conversations feel especially timely as the field continues to look beyond anatomy alone, and instead toward a deeper understanding of plaque biology, lesion-level risk, and increasingly personalized cardiovascular care. CEO Kelly Huang, and Lead Scientific Advisor @amir_ahmadi__, will be joining the community in Portugal, and we’re looking forward to the ideas, debate, and collaboration ahead. See you in beautiful Vilamoura! 🇵🇹 @MillbrookMed @imperialcollege #vulnerableplaque #cardiology #atherosclerosis #cardiovascularimaging #CCTA #precisionmedicine

What separates meaningful healthcare AI from the hype? For Elucid CEO Kelly Huang, it comes down to what AI enables physicians to understand, and whether that information can lead to a better-informed clinical decision. In a new @AdvaMedUpdate \ Insight Series: AI & Digital Health interview (advamed.org/2026/08/27/the-i…), Kelly discusses why the next generation of cardiovascular AI needs to go beyond efficiency alone. He explores the evolution toward CCTA 3.0, where anatomy, plaque biology, and physiology come together at the lesion level; the importance of transparent, explainable and scientifically validated AI; and why directly understanding a patient’s disease could help enable more personalized cardiovascular care. As Kelly puts it: “We can’t out-efficiency a diagnostic blind spot.” Thank you to AdvaMed for the opportunity to share our perspective on where AI can make a meaningful difference in cardiovascular care. #AIinhealthcare #digitalhealth #cardiology #cardiovascularimaging #CCTA #precisionmedicine #medtech

“The lesion is where risk becomes an event.” Individual plaques are where pathways of atherosclerosis progression, rupture, and erosion ultimately converge. By better characterizing risk at the lesion level, and then combining those insights to understand the patient as a whole, we can move toward more personalized risk assessment and, ultimately, more personalized therapy. See the full symposium for the broader discussion on CCTA 3.0, plaque biology, physiology, workflow, and the future of personalized cardiovascular care. Excerpt featuring Dr. Michael Hadley, Northwell. 📺: piped.video/watch?v=Tz6MCKEI… #yesCCT #cardiology #cardiovascularimaging #coronaryarterydisease #precisionmedicine #medtech

piped.video/watch?v=0baR_-3k… Elucid CEO Kelly Huang, PhD recently shared our vision for where cardiovascular imaging is headed next: CCTA 3.0. The core idea is simple: anatomy, plaque biology, and physiology should not be viewed in isolation. By integrating all three at the lesion level, physicians can gain a more complete understanding of disease and move toward more personalized treatment decisions. Hear about the scientific foundation behind Elucid’s approach, from histology-based plaque characterization and BioIntegrated FFR-CT* to transparency, workflow, and the clinical research needed to advance lesion-level risk assessment. *FFR-CT is under FDA review. #SCCT2026 #yesCCT #cardiology #cardiovascularimaging #AIinhealthcare #precisionmedicine

In this excerpt from our recent webinar, Dr. Hiram Bezerra walks through a complex multi-vessel case and shows how he used #CCTA-based plaque composition, lesion distribution, and physiology to plan procedural strategy in advance. 📺 Full webinar: piped.video/YyS0DX6e3eA?si=q5Qs… #cardiology #interventionalcardiology #yesCCT #coronaryarterydisease #plaqueanalysis #cathlab #precisionmedicine

Can two coronary lesions with the same degree of stenosis behave differently? In this clip, @amir_ahmadi__ explains why coronary arteries can't simply be thought of as rigid pipes. Plaque composition, vessel remodeling, and the biological behavior of the vessel during maximal hyperemia all influence physiology, meaning lesions with similar anatomical narrowing may produce very different functional outcomes. It's one reason why the future of #yesCCT lies in integrating plaque biology and lesion-level physiology, providing a deeper understanding of coronary artery disease and supporting more personalized clinical decision-making. Full webinar featuring Dr. Amir Ahmadi and Dr. Hiram Bezerra: piped.video/watch?v=YyS0DX6e… #cardiology #CCTA #cardiovascularimaging #precisionmedicine #medtech

For years, cardiovascular risk assessment has often focused on individual measures such as stenosis, plaque composition, and physiology as if they were competing ways to understand disease. In our recent webinar hosted by @Heart_SCCT, @amir_ahmadi__ shares why that paradigm is changing. With today's advances in CCTA and AI, these previous competing metrics have become complementary components of a more complete understanding of coronary artery disease. The future lies in integrating plaque biology, lesion-level physiology, and anatomy into a single comprehensive assessment, enabling physicians to move from lesion-level risk to patient-level impact and support more personalized clinical decision-making. Watch the full webinar, including case discussions with Dr. Hiram Bezerra and a look at how comprehensive CCTA analysis may help inform interventional planning: 📺 piped.video/watch?v=YyS0DX6e… #cardiology #yesCCT #precisionmedicine #coronaryarterydisease #cardiovascularimaging #medtech

Stop by booth 210 today at #ASPC2026 to experience a live demo of our latest product features! Come see how a comprehensive plaque analysis joining biology and physiology can enhance your preventive cardiology program. @ASPCardio

Last chance to register ➡️ scct.org/events/EventDetails… Don't miss out on the opportunity to hear from Dr. Amir Ahmadi (@amir_ahmadi__) and Dr. Hiram Bezerra as they explore what's driving the evolution of CCTA 3.0: from advanced plaque analysis and lesion-level physiology to the latest interventional therapies that are changing how we diagnose and treat coronary artery disease. We'll also be sharing case demonstrations, discussing upcoming clinical research, and answering your questions live. Thank you @Heart_SCCT for hosting! #cardiology #yesCCT #cardiovascularimaging #precisionmedicine #medtech #preventivecardiology #interventionalcardiology

Register here: scct.org/events/EventDetails… 🗓️ Join us next Wednesday, July 29 at 12PM ET for a live webinar exploring the next evolution of coronary CT angiography! Hosted by @Heart_SCCT, this session features @amir_ahmadi__ and Dr. Hiram Bezerra as they discuss how advanced plaque characterization, lesion-level physiology assessment, and emerging interventional therapies are converging to enable more personalized cardiovascular diagnosis and treatment planning. Through real-world case examples, you'll gain insights into: • The evolution toward CCTA 3.0 • How plaque biology and lesion-level assessment can enhance clinical decision-making • Upcoming research The discussion will be moderated by Kelly Huang, CEO of Elucid. Can't attend live? Register anyway, and we'll send you the webinar recording after the event. Thank you to the SCCT for hosting this educational event 🫀 #cardiology #CCTA #yesCCT #cardiovascularimaging #preventivecardiology #interventionalcardiology #medicalimaging #precisionmedicine

Every breakthrough starts with a question. For us, that question was: How can we bring the biological truth of plaque into non-invasive CT imaging? 🔬 Our journey began with histology, the gold standard for understanding plaque biology. Years of research, development, and validation have helped transform those microscopic insights into non-invasive plaque analysis, enabling physicians to see beyond anatomy alone and move toward more personalized cardiovascular care. 📖 This is the story behind our mission, and the science that continues to drive it forward. Stay tuned for more! #cardiology #yesCCT #cardiovascularimaging #plaqueanalysis

☀️ We're proud to be recognized as a Quantum Certified Workplace ☀️ At Elucid, our success starts with building a workplace where talented people are empowered to collaborate, innovate, and do their best work. This recognition reflects the culture our team has built together, and we're grateful to every employee who makes Elucid such a special place to work 😎 As Amy Kruglak, our SVP of People says, "We put a lot into our people and our culture every day, so receiving this recognition is incredibly meaningful. It also reflects that our people-first culture is one of Elucid's greatest strengths and a true differentiator as we continue to grow." #QuantumCertifiedWorkplace #companyculture #teamelucid

We're headed to #ASPC2026 in just a couple weeks! Stop by booth 210 to catch up on all the new developments going on at Elucid - including plaque based FFR-CT, stenosis quantification, and a new comprehensive user interface that enables efficient and transparent clinical insights. See you in Scottsdale! 🛫 🌵 @ASPCardio #preventivecardiology #yesCCT #plaqueanalysis #FFRCT *FFR-CT and Stenosis are under FDA review.

How can plaque biology and lesion physiology help guide more personalized treatment decisions? 🔊 Join Dr. Amir Ahmadi (Mount Sinai) @amir_ahmadi__ and Dr. Hiram Bezerra (University of South Florida/Tampa General) on Wednesday, July 29 at 12:00 PM ET for an educational webinar exploring the evolution of CCTA. Register: scct.org/events/EventDetails… Building on many of the key themes presented at #SCCT2026, the discussion will examine the scientific foundation behind advanced plaque analysis, integrated plaque-derived physiology, and the growing role of CCTA in supporting personalized cardiovascular care. Through real-world cases, including interventional perspectives shared by Dr. Bezerra, we will explore how lesion-level insights may help inform treatment strategies and clinical decision-making. #cardiology #CCTA #yesCCT #cardiovascularimaging #interventionalcardiology #precisionmedicine

Thank you to the beautiful SCCT community for another great Annual Scientific Meeting. So many productive conversations, valuable feedback, and collaborative sessions. We’re definitely walking out of here with a pep in our step! Time to hit the wave pool! 🌊 Until next time, Elucid Proud supporters of @Heart_SCCT ❤️ #yesCCT